메뉴 건너뛰기




Volumn 71, Issue 4, 2014, Pages 754-759

Managing skin toxicities related to panitumumab

Author keywords

Common Toxicity Criteria for Adverse Events; Epidermal growth factor receptor inhibitors; Panitumumab; Papulopustular rash; Skin toxicity

Indexed keywords

ANTIINFECTIVE AGENT; PANITUMUMAB; ANTINEOPLASTIC AGENT; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

EID: 84910131661     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.06.011     Document Type: Article
Times cited : (11)

References (31)
  • 1
    • 85055522508 scopus 로고    scopus 로고
    • Erbitux (cetuximab) [package insert], NJ: Bristol-Myers Squibb
    • Erbitux (cetuximab) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2007.
    • (2007) Princeton
  • 2
    • 79959835735 scopus 로고    scopus 로고
    • Vectibix (panitumumab) [product monograph], Ontario, Canada: Amgen
    • Vectibix (panitumumab) [product monograph]. Mississauga, Ontario, Canada: Amgen; 2008.
    • (2008) Mississauga
  • 3
    • 85030408649 scopus 로고    scopus 로고
    • Iressa (gefitinib) [package insert], Ontario, Canada: Astra Zeneca
    • Iressa (gefitinib) [package insert]. Mississauga, Ontario, Canada: Astra Zeneca; 2011.
    • (2011) Mississauga
  • 4
    • 79951760967 scopus 로고    scopus 로고
    • Tarceva (erlotinib) [package insert], Ontario, Canada: Hoffman-La Roche Ltd
    • Tarceva (erlotinib) [package insert]. Mississauga, Ontario, Canada: Hoffman-La Roche Ltd; 2009.
    • (2009) Mississauga
  • 5
    • 84872844201 scopus 로고    scopus 로고
    • The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients
    • Ra HS, Shin SJ, Kim JH, Lim H, Cho BC, Roh MR. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients. J Eur Acad Dermatol Venereol 2013;27:e53-9.
    • (2013) J Eur Acad Dermatol Venereol , vol.27 , pp. e53-e59
    • Ra, H.S.1    Shin, S.J.2    Kim, J.H.3    Lim, H.4    Cho, B.C.5    Roh, M.R.6
  • 6
    • 84880865947 scopus 로고    scopus 로고
    • Impact of dermatologic adverse events on quality of life in 283 cancer patients: A questionnaire study in a dermatology referral clinic
    • Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Clin Dermatol 2013;14:327-33.
    • (2013) Clin Dermatol , vol.14 , pp. 327-333
    • Rosen, A.C.1    Case, E.C.2    Dusza, S.W.3    Balagula, Y.4    Gordon, J.5    West, D.P.6
  • 7
    • 84866646369 scopus 로고    scopus 로고
    • Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
    • Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, et al. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer 2012;12: 438.
    • (2012) BMC Cancer , vol.12 , pp. 438
    • Thaler, J.1    Karthaus, M.2    Mineur, L.3    Greil, R.4    Letocha, H.5    Hofheinz, R.6
  • 8
    • 38549142436 scopus 로고    scopus 로고
    • Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results
    • Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007;72:152-9.
    • (2007) Oncology , vol.72 , pp. 152-159
    • Boone, S.L.1    Rademaker, A.2    Liu, D.3    Pfeiffer, C.4    Mauro, D.J.5    Lacouture, M.E.6
  • 9
    • 36849093857 scopus 로고    scopus 로고
    • Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab associated acne-like eruption
    • Scope A, Agero AL, Dusza SW. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab associated acne-like eruption. J Clin Oncol 2007;25: 5390-6.
    • (2007) J Clin Oncol , vol.25 , pp. 5390-5396
    • Scope, A.1    Agero, A.L.2    Dusza, S.W.3
  • 10
    • 66749140972 scopus 로고    scopus 로고
    • A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption
    • Scope A, Lieb JA, Disza SW. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 2009;61:614-20.
    • (2009) J Am Acad Dermatol , vol.61 , pp. 614-620
    • Scope, A.1    Lieb, J.A.2    Disza, S.W.3
  • 11
    • 84855919382 scopus 로고    scopus 로고
    • The management of EGFR inhibitor adverse events: A case series and treatment paradigm
    • Wnorowski AM, de Souza A, Chachoua A, Cohen DE. The management of EGFR inhibitor adverse events: a case series and treatment paradigm. Int J Dermatol 2012;51:223-32.
    • (2012) Int J Dermatol , vol.51 , pp. 223-232
    • Wnorowski, A.M.1    De Souza, A.2    Chachoua, A.3    Cohen, D.E.4
  • 12
    • 84882889101 scopus 로고    scopus 로고
    • Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non small cell lung cancer
    • Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non small cell lung cancer. J Am Acad Dermatol 2013;69: 463-72.
    • (2013) J Am Acad Dermatol , vol.69 , pp. 463-472
    • Kiyohara, Y.1    Yamazaki, N.2    Kishi, A.3
  • 13
    • 42649145667 scopus 로고    scopus 로고
    • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
    • (2008) J Clin Oncol , vol.26 , pp. 1626-1634
    • Amado, R.G.1    Wolf, M.2    Peeters, M.3    Van Cutsem, E.4    Siena, S.5    Freeman, D.J.6
  • 14
    • 34547586714 scopus 로고    scopus 로고
    • Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer
    • Lacouture ME. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. Cancer Nurs 2007;30:S17-26.
    • (2007) Cancer Nurs , vol.30 , pp. S17-26
    • Lacouture, M.E.1
  • 15
    • 4344646459 scopus 로고    scopus 로고
    • Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
    • Perez-Soler R, Chachoua A. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47.
    • (2004) J Clin Oncol , vol.22 , pp. 3238-3247
    • Perez-Soler, R.1    Chachoua, A.2
  • 16
    • 84984568870 scopus 로고    scopus 로고
    • MASCC skin toxicity study group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
    • Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011;19:1079-95.
    • (2011) Support Care Cancer , vol.19 , pp. 1079-1095
    • Lacouture, M.E.1    Anadkat, M.J.2    Bensadoun, R.J.3    Bryce, J.4    Chan, A.5    Epstein, J.B.6
  • 17
    • 78751622165 scopus 로고    scopus 로고
    • Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors
    • Balagula Y, Garbe C, Myskowski P, Haushild A, Rapoport B, Boers-Doets CB, et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 2011;50:129-46.
    • (2011) Int J Dermatol , vol.50 , pp. 129-146
    • Balagula, Y.1    Garbe, C.2    Myskowski, P.3    Haushild, A.4    Rapoport, B.5    Boers-Doets, C.B.6
  • 18
    • 20844448897 scopus 로고    scopus 로고
    • HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum
    • Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345-56.
    • (2005) Oncologist , vol.10 , pp. 345-356
    • Pérez-Soler, R.1    Delord, J.P.2    Halpern, A.3    Kelly, K.4    Krueger, J.5    Sureda, B.M.6
  • 19
    • 77951879709 scopus 로고    scopus 로고
    • Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: A case series and a literature review of therapeutic approaches
    • Nikolaou V, Stratigos A, Antoniou C, Kiagia M, Nikolaou C, Katsambas A, et al. Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches. Dermatology 2010;220:243-8.
    • (2010) Dermatology , vol.220 , pp. 243-248
    • Nikolaou, V.1    Stratigos, A.2    Antoniou, C.3    Kiagia, M.4    Nikolaou, C.5    Katsambas, A.6
  • 20
    • 84875044772 scopus 로고    scopus 로고
    • Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer
    • Jo JC, Hong YS, Kim KP, Lee JL, Kim HJ, Lee MW, et al. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. Eur J Dermatol 2013;23: 77-82.
    • (2013) Eur J Dermatol , vol.23 , pp. 77-82
    • Jo, J.C.1    Hong, Y.S.2    Kim, K.P.3    Lee, J.L.4    Kim, H.J.5    Lee, M.W.6
  • 21
    • 47849098042 scopus 로고    scopus 로고
    • Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects
    • Pomerantz RG, Chirinos RE, Falo LD, Geskin LJ. Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects. Arch Dermatol 2008;144:949-50.
    • (2008) Arch Dermatol , vol.144 , pp. 949-950
    • Pomerantz, R.G.1    Chirinos, R.E.2    Falo, L.D.3    Geskin, L.J.4
  • 22
    • 77950495095 scopus 로고    scopus 로고
    • Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer
    • Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:1351-7.
    • (2010) J Clin Oncol , vol.28 , pp. 1351-1357
    • Lacouture, M.E.1    Mitchell, E.P.2    Piperdi, B.3    Pillai, M.V.4    Shearer, H.5    Iannotti, N.6
  • 23
    • 84984570566 scopus 로고    scopus 로고
    • How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors
    • Chan A, Tan EH. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer 2011;19:1667-74.
    • (2011) Support Care Cancer , vol.19 , pp. 1667-1674
    • Chan, A.1    Tan, E.H.2
  • 24
    • 3242881591 scopus 로고    scopus 로고
    • National Cancer Institute. Accessed September 9
    • National Cancer Institute. Common Toxicity Criteria for Adverse Events. Available from: URL: http://evs.nci.nih.gov/ ftp1/CTCAE/About.html. Accessed September 9, 2013.
    • (2013) Common Toxicity Criteria for Adverse Events
  • 25
    • 35548969264 scopus 로고    scopus 로고
    • Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management
    • Lynch T, Kim ES, Eaby B, Garey J, West DP, Lacouture M. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12:610-21.
    • (2007) Oncologist , vol.12 , pp. 610-621
    • Lynch, T.1    Kim, E.S.2    Eaby, B.3    Garey, J.4    West, D.P.5    Lacouture, M.6
  • 26
    • 84922703239 scopus 로고    scopus 로고
    • University Health Network. Accessed October 1
    • University Health Network. Our hospitals: Princess Margaret Cancer Center. Available from: URL: http://www.uhn.ca/corporate/ AboutUHN/OurHospitals/Pages/PMCC.aspx. Accessed October 1, 2013.
    • (2013) Our Hospitals: Princess Margaret Cancer Center
  • 27
    • 84908418476 scopus 로고    scopus 로고
    • R core team. R: A language and environment for statistical computing
    • Accessed October , Vienna (Austria)
    • R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna (Austria). Available from: URL:http://www.R-project. org/. Accessed October 2013.
    • (2013) R Foundation for Statistical Computing
  • 28
    • 34447129570 scopus 로고    scopus 로고
    • Correlation between development of rash and efficacy in patients treated with epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
    • Wacker B, Nagrani T, Weinberg J, Witt K. Correlation between development of rash and efficacy in patients treated with epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13:3913-21.
    • (2007) Clin Cancer Res , vol.13 , pp. 3913-3921
    • Wacker, B.1    Nagrani, T.2    Weinberg, J.3    Witt, K.4
  • 29
    • 65749101493 scopus 로고    scopus 로고
    • Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations
    • Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009;16: 16-26.
    • (2009) Curr Oncol , vol.16 , pp. 16-26
    • Melosky, B.1    Burkes, R.2    Rayson, D.3    Alcindor, T.4    Shear, N.5    Lacouture, M.6
  • 30
    • 84875878144 scopus 로고    scopus 로고
    • A real life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: A retrospective analysis at the Jewish General Hospital, 2009-2012
    • Mamo A, Nogueira MC, Batist G, Palumbo M, Panasci L, Ferrario C, et al. A real life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012. Curr Oncol 2013;20:e107-12.
    • (2013) Curr Oncol , vol.20 , pp. e107-e112
    • Mamo, A.1    Nogueira, M.C.2    Batist, G.3    Palumbo, M.4    Panasci, L.5    Ferrario, C.6
  • 31
    • 84899981129 scopus 로고    scopus 로고
    • Panitumumab versus cetuximab in patients with chemotherapyrefractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study
    • Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. Panitumumab versus cetuximab in patients with chemotherapyrefractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014;15:569-79.
    • (2014) Lancet Oncol , vol.15 , pp. 569-579
    • Price, T.J.1    Peeters, M.2    Kim, T.W.3    Li, J.4    Cascinu, S.5    Ruff, P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.